"Arcutis’ Roflumilast Cream Could Be “Game Changer” for Plaque Psoriasis"
Arcutis Biotherapeutics, Inc.’s Roflumilast cream (ARQ-151) produced significant improvements in patients with plaque psoriasis in as early as two weeks, according to a results from a phase 2b trial published in The New England Journal of Medicine.
Press Release
Mount Sinai Researchers Discover That Topical Treatment Improves Chronic Plaque Psoriasis
Jul 15, 2020 View All Press Releases